您的位置: 首页 > 2022年7月 第52卷 第4期 > 文字全文
2023年7月 第38卷 第7期11
目录

胰岛素联合乌司他丁在高脂血症性重症胰腺炎中的评价

Evaluation of curative effect of insulin combined with ulinastatin on hyperlipidemic severe pancreatitis

来源期刊: 广州医药 | 83-88 发布时间:2022-08-03 收稿时间:2025/11/13 18:20:18 阅读量:25
作者:
关键词:
急性重症胰腺炎高脂血症胰岛素乌司他丁联合治疗
severe acute pancreatitishyperlipidemicinsulinulinastatincombination therapy
DOI:
10.3969/j.issn.1000-8535.2022.04.019
收稿时间:
2021-10-02 
修订日期:
 
接收日期:
 
引用总数:
6  
目的 探讨胰岛素联合乌司他丁在高脂血症性重症胰腺炎中的临床疗效。方法 研究资料来自广州市花都区人民医院肝胆胰外科自2018年—2020年收治的72例高脂血症性重症胰腺炎患者资料,所有患者按照不同治疗方案随机分为3组,每组各24例。对照组采用急性胰腺炎常规治疗(即生长抑素+液体疗法);乌司他丁组则于常规组上联用乌司他丁;而研究组在常规及联合乌司他丁治疗基础上加用胰岛素强化治疗,比较3组患者腹痛及胃肠功能恢复的时间、甘油三酯下降的水平,治疗前、治疗后第3天、7天的APACHE Ⅱ评分的变化情况。结果 研究组患者腹痛症状缓解及胃肠功能恢复时间均较对照组明显缩短、腹痛症状缓解时间较乌司他丁组缩短,且研究组甘油三酯下降水平较对照组和乌司他丁组快,而研究组第3天和第7天的APACHE-Ⅱ评分较常规组及乌司他丁组低,以上差别均有统计学意义(P<0.05)。结论 胰岛素联合乌司他丁可明显改善高脂血症合并重症急性胰腺炎腹部症状、缩短胃肠功能恢复时间、迅速降低血清甘油三酯水平,对患者近期疗效确切。
Objective To explore curative effect of insulin combined with ulinastatin in therapy of severe hyperlipidemic pancreatitis. Methods A total of 72 patients with hyperlipidemia complicated with severe acute pancreatitis were randomly divided into three groups according to different treatment plans, 24 cases in each group. The regular treatment of acute pancreatitis (somatostatin+liquid therapy) was carried out in control group. Base on the regular treatment of acute pancreatitis, ulinastatin was added in ulinastatin group. Base on the treatment of ulinastatin group, insulin was added in study group, and the time of abdominal pain and gastrointestinal function recovery, glycerin level and the APACHE Ⅱ score before and after treatment among three groups were compared. Results Compared with the control group and ulinastatin group, the time of abdominal pain relief and gastrointestinal function recovery in the study group were significantly shorter, the time of triglycerides level back to normal in the study group was shorter than the other two groups, while at the third and seventh day, the APACHE Ⅱ score of the study group was lower than that of other two groups, with statistical significance (P<0.05). Conclusions Insulin combined with ulinastatin could significantly improve abdominal symptoms of hyperlipidemia complicated with severe acute pancreatitis, promote the recovery of gastrointestinal function, and rapidly reduce the level of serum triglyceride.
1、 王俊,金钧,黄坚,等.早期使用乌司他丁对中重症/重症急性胰腺炎患者疗效的影响[J]. 中华医学杂志,2017,97(16):1252-1255. 王俊,金钧,黄坚,等.早期使用乌司他丁对中重症/重症急性胰腺炎患者疗效的影响[J]. 中华医学杂志,2017,97(16):1252-1255.
2、 WANG Y J, LI L.Predicative values of C-reactive protein for the therapeutic effects of ulinastatin combined with somatostatin in severe acute pancreatitis and for the severity of gastrointestinal failure[J]. Exp Ther Med,2018,16(4):3165-3171. WANG Y J, LI L.Predicative values of C-reactive protein for the therapeutic effects of ulinastatin combined with somatostatin in severe acute pancreatitis and for the severity of gastrointestinal failure[J]. Exp Ther Med,2018,16(4):3165-3171.
3、 肖先水,苏晋簇,蒋佑成.低分子肝素、胰岛素联合治疗高脂血症性急性胰腺炎的疗效观察[J]. 中华胰腺病杂志,2017,17(4):265-267. 肖先水,苏晋簇,蒋佑成.低分子肝素、胰岛素联合治疗高脂血症性急性胰腺炎的疗效观察[J]. 中华胰腺病杂志,2017,17(4):265-267.
4、 吴光理,朱子宜.强化血糖控制对急性胰腺炎患者血糖波动及新发糖尿病的影响[J]. 浙江临床医学,2017,19(1):113-114. 吴光理,朱子宜.强化血糖控制对急性胰腺炎患者血糖波动及新发糖尿病的影响[J]. 浙江临床医学,2017,19(1):113-114.
5、 ALTINKAVA E, AKTAS A. Insulin and heparin therapies in acute pancreatitis due to hypertriglyceridemia[J]. J Coll Physicians Surg Pak, 2021,31(11):1337-1340. ALTINKAVA E, AKTAS A. Insulin and heparin therapies in acute pancreatitis due to hypertriglyceridemia[J]. J Coll Physicians Surg Pak, 2021,31(11):1337-1340.
6、 RAWLA P, SUNKARA T, THANDRA K C, et al. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies[J]. Clin J Gastroenterol,2018,11(6):441-448. RAWLA P, SUNKARA T, THANDRA K C, et al. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies[J]. Clin J Gastroenterol,2018,11(6):441-448.
7、 INAYAT F, ZAFAR F, RIAZ I, et al. Hypertriglyceridemic pancreatitis: is insulin monotherapy a feasible therapeutic option?[J] Cureus,2018,10(10):e3461. INAYAT F, ZAFAR F, RIAZ I, et al. Hypertriglyceridemic pancreatitis: is insulin monotherapy a feasible therapeutic option?[J] Cureus,2018,10(10):e3461.
8、 AYYAVOO A, RAGHUPATHY P, AGARWAL M, et al. Severe familial hypertriglyceridemia: successful treatment with insulin and a modified meal plan[J]. J Endocr Soc, 2018 ,2(12):1357-1362. AYYAVOO A, RAGHUPATHY P, AGARWAL M, et al. Severe familial hypertriglyceridemia: successful treatment with insulin and a modified meal plan[J]. J Endocr Soc, 2018 ,2(12):1357-1362.
9、 KUCHAY M S, FAROOQUI K J, BANO T, et al. Heparin and insulin in the management of hypertriglyceridemia-associated pancreatitis: case series and literature review[J]. Arch Endocrinol Metab, 2017,61(2):198-201. KUCHAY M S, FAROOQUI K J, BANO T, et al. Heparin and insulin in the management of hypertriglyceridemia-associated pancreatitis: case series and literature review[J]. Arch Endocrinol Metab, 2017,61(2):198-201.
10、 SONG X, SHI D, CUI Q, et al. Intensive insulin therapy versus plasmapheresis in the management of hypertriglyceridemia-induced acute pancreatitis (Bi-TPAI trial): study protocol for a randomized controlled trial[J]. Trials, 2019,20(1):365-365. SONG X, SHI D, CUI Q, et al. Intensive insulin therapy versus plasmapheresis in the management of hypertriglyceridemia-induced acute pancreatitis (Bi-TPAI trial): study protocol for a randomized controlled trial[J]. Trials, 2019,20(1):365-365.
11、 SAHU K K, MISHRA A K, LAL A, et al. Update on management of hypertriglyceridaemia-induced acute pancreatitis[J]. BMJ Case Rep, 2019, 12(8):e231703. SAHU K K, MISHRA A K, LAL A, et al. Update on management of hypertriglyceridaemia-induced acute pancreatitis[J]. BMJ Case Rep, 2019, 12(8):e231703.
12、 LUDES P O, de ROQUETAILLADE C, CHOUSTERMAN B G, et al. Role of damage-associated molecular patterns in septic acute kidney injury, from injury to recovery[J]. Front Immunol,2021, 1(12):606-622. LUDES P O, de ROQUETAILLADE C, CHOUSTERMAN B G, et al. Role of damage-associated molecular patterns in septic acute kidney injury, from injury to recovery[J]. Front Immunol,2021, 1(12):606-622.
13、 YAN Z, ZANG B, GONG X, et al. MiR-214-3p exacerbates kidney damages and inflammation induced by hyperlipidemic pancreatitis complicated with acute renal injury[J]. Life Sci,2020,15(241):117-118. YAN Z, ZANG B, GONG X, et al. MiR-214-3p exacerbates kidney damages and inflammation induced by hyperlipidemic pancreatitis complicated with acute renal injury[J]. Life Sci,2020,15(241):117-118.
14、 JIN M, BAI X, CHEN X, et al. A 16-year trend of etiology in acute pancreatitis: The increasing proportion of hypertriglyceridemia-associated acute pancreatitis and its adverse effect on prognosis[J]. J Clin Lipidol, 2019,13(6):947-953. JIN M, BAI X, CHEN X, et al. A 16-year trend of etiology in acute pancreatitis: The increasing proportion of hypertriglyceridemia-associated acute pancreatitis and its adverse effect on prognosis[J]. J Clin Lipidol, 2019,13(6):947-953.
15、 中国中西医结合学会普通外科专业委员会.重症急性胰腺炎中西医结合诊治指南(2014年,天津)[J]. 临床肝胆病杂志,2015,31(3):327-331. 中国中西医结合学会普通外科专业委员会.重症急性胰腺炎中西医结合诊治指南(2014年,天津)[J]. 临床肝胆病杂志,2015,31(3):327-331.
16、 中华医学会消化病学分会胰腺疾病学组,《中华胰腺病杂志》编委会,《中华消化杂志》编委会.中国急性胰腺炎诊治指南(2019年,沈阳)[J]. 临床肝胆病杂志,2019,35(12):2706-2711. 中华医学会消化病学分会胰腺疾病学组,《中华胰腺病杂志》编委会,《中华消化杂志》编委会.中国急性胰腺炎诊治指南(2019年,沈阳)[J]. 临床肝胆病杂志,2019,35(12):2706-2711.
17、 YANG A L, MCNABB-BALTAR J. Hypertriglyceridemia and acute pancreatitis[J]. Pancreatology,2020,20(5):795-800. YANG A L, MCNABB-BALTAR J. Hypertriglyceridemia and acute pancreatitis[J]. Pancreatology,2020,20(5):795-800.
18、 朱亮,祝荫,何文华, 等.江西省2 625例急性胰腺炎临床特征分析[J]. 中华消化杂志,2014,34(8):531-534. 朱亮,祝荫,何文华, 等.江西省2 625例急性胰腺炎临床特征分析[J]. 中华消化杂志,2014,34(8):531-534.
19、 CROCKETT S D, WANI S, GARDNER T B,et al. American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis[J]. Gastroenterology,2018,154(4):1096-1101. CROCKETT S D, WANI S, GARDNER T B,et al. American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis[J]. Gastroenterology,2018,154(4):1096-1101.
20、 LEE P J, PAPACHRISTOU G I. New insights into acute pancreatitis[J]. Nat Rev Gastroenterol Hepatol,2019,16(8):479-496. LEE P J, PAPACHRISTOU G I. New insights into acute pancreatitis[J]. Nat Rev Gastroenterol Hepatol,2019,16(8):479-496.
21、 SIREGAR G A, SIREGAR G P. Management of severe acute pancreatitis[J]. Open Access Maced J Med Sci,2019,7(19):3319-3323. SIREGAR G A, SIREGAR G P. Management of severe acute pancreatitis[J]. Open Access Maced J Med Sci,2019,7(19):3319-3323.
22、 GREENBERG J A, HSU J, BAWAZEER M, et al. Clinical practice guideline: management of acute pancreatitis[J]. Can J Surg,2016,59(2):128-140. GREENBERG J A, HSU J, BAWAZEER M, et al. Clinical practice guideline: management of acute pancreatitis[J]. Can J Surg,2016,59(2):128-140.
1、王琦聪,李梅燕. 乌司他丁联合胰岛素强化治疗对高脂血症急性胰腺炎临床效果的影响[J]. 中外医学研究,2025,23(18):50-53. DOI:10.14033/j.cnki.cfmr.2025.18.014.王琦聪,李梅燕. 乌司他丁联合胰岛素强化治疗对高脂血症急性胰腺炎临床效果的影响[J]. 中外医学研究,2025,23(18):50-53. DOI:10.14033/j.cnki.cfmr.2025.18.014.
2、柯达,何宇敏.小剂量胰岛素泵入联合非诺贝特对高脂性胰腺炎的疗效评价[J].北方药学,2023,20(07):53-54+57. 柯达,何宇敏.小剂量胰岛素泵入联合非诺贝特对高脂性胰腺炎的疗效评价[J].北方药学,2023,20(07):53-54+57.
3、周涛,孙超艳,闫登峰.重症急性胰腺炎患者的抗炎症反应药物治疗效果分析[J].中国药物评价,2024,41(05):414-418. 周涛,孙超艳,闫登峰.重症急性胰腺炎患者的抗炎症反应药物治疗效果分析[J].中国药物评价,2024,41(05):414-418.
4、刘贵生,邓燕珍,廖长发.常规补液联合胰岛素对高脂血症性急性胰腺炎患者的临床效果[J].西藏医药,2025,46(04):41-43. 刘贵生,邓燕珍,廖长发.常规补液联合胰岛素对高脂血症性急性胰腺炎患者的临床效果[J].西藏医药,2025,46(04):41-43.
5、石婷婷,翁建斌,黎金明.乌司他丁联合胰岛素泵持续皮下给药治疗糖尿病酮症酸中毒合并感染性休克的临床效果与安全性[J].糖尿病新世界,2025,28(21):21-24.DOI:10.16658/j.cnki.1672-4062.2025.21.021. 石婷婷,翁建斌,黎金明.乌司他丁联合胰岛素泵持续皮下给药治疗糖尿病酮症酸中毒合并感染性休克的临床效果与安全性[J].糖尿病新世界,2025,28(21):21-24.DOI:10.16658/j.cnki.1672-4062.2025.21.021.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录